



Media Contact:

John Cashman, Ph.D.
Human BioMolecular Research Institute
San Diego, California, 92121
JCashman@hbri.org
(858) 458-9305

For Immediate Release

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Cardiovascular Properties and Metabolism and Pharmacokinetics of Deuterated Mexiletine Analogs

In the United States, almost one million individuals are hospitalized every year for cardiac arrhythmias, making arrhythmias one of the top causes of healthcare expenditures with a direct cost of almost \$50 billion annually. Almost 300,000 individuals die of sudden arrhythmic death syndrome every year.

Ventricular cardiac arrhythmia arises in acquired or congenital heart disease. Arrhythmias are very common in older adults but unfortunately, drugs to treat arrhythmias have liabilities. In addition, numerous investigational drugs have been withdrawn from the market because they induce QT prolongation and a potentially fatal ventricular tachycardia, a condition called Torsade de Pointes.

For normal heart cell function, sodium channels rapidly inactivate with depolarization. In depolarization of cardiomyocytes, sodium channels open briefly and allow influx of sodium. Correct regulation of ion currents in cardiomyocytes is key for proper heart function.

Cardiac action potential is initiated by the opening of the cardiac sodium channel conducting the large peak sodium current responsible for the action potential upstroke. In healthy individuals, sodium channels inactivate with depolarization. However, Long QT syndrome type 3 (LQT3) patients have mutations in the sodium channel that impair channel inactivation and accelerate recovery from the inactivated state. Increased sodium

channel current opposes repolarization and prolongs the action potential, thus prolonging the QT interval on the surface electrocardiogram.

Mexiletine is a drug that inhibits the sodium current and shortens the QT interval in LQT3 patients and decreases their risk of developing ventricular tachycardia and ventricular fibrillation. Blockade of voltage-gated sodium channels that inhibits generation and propagation of action potentials can be antiarrhythmic and prevent pathological firing in cardiac tissue. However, mexiletine has liabilities. The FDA Approved Label states that severe liver injury and blood dyscrasias (i.e., leukopenia or agranulocytosis) and other adverse reactions including reversible gastrointestinal and nervous system problems have been reported after mexiletine treatment. Accordingly, in our studies, new mexiletine analogs were designed to improve pharmaceutical properties, increase the potency and improve the therapeutic to toxicity ratio.

We tested the hypothesis that a useful drug (i.e., mexiletine) with liabilities (i.e., potassium channel inhibition and adverse reactions) and a relatively short half-life could be re-engineered by dynamic medicinal chemistry and evaluated in normal and human patient induced pluripotent stem cell-derived cardiomyocytes to afford new drug candidates with greater efficacy and less toxicity. Medicinal chemists and stem cell biologists at the Human BioMolecular Research Institute (HBRI), in San Diego, CA, and Stanford University, in Stanford, CA, respectively, reported on reengineered mexiletine compounds that showed improved potency and decreased toxicity.

The report showed that application of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to evaluate proarrhythmic effects of deuterated mexiletine analogs helped define chemical determinants responsible for anti-arrhythmia and improve the pharmaceutical properties of the drug candidates. In parallel, patient-derived hiPSC-CMs carrying a LQT3 sodium channel mutation were used to quantify the extent of action potential shortening of deuterated mexiletine analogues. Human LQT3 CMs were used to determine deuterated mexiletine analog beneficial effects, quantified as the potency for shortening the action potential duration, fold-shortening of the action potential duration and a concentration that caused shortening of the action potential. These results were compared to the concentration of a test compound required for cessation of cell beating, potency for shortening the action potential duration, and fold-shortening of the action potential duration in normal cardiomyocytes. The results led to identification of potent and selective sodium channel inhibitors with decreased proarrhythmic effects and improved physicochemical and pharmaceutical properties. Compounds were shown to be effective antiarrhythmic compounds in hiPSC-CM models of LQT3-associated arrhythmia.

This paper was featured in *Pharmacology Research & Perspectives*. Writing on July, 2021:

“The finding that “drug discovery in a dish” using a deuterated drug candidate approach was successful is important because it showed that human drug development can be done efficiently using these approaches” explains lead author Dr. Jorge Gomez-Galeno.

“By selectively blocking a sodium channel in human cardiomyocytes, and decreasing off-target effects, new and safer drugs can be developed.” Given its potency, these new compounds may be of utility as antiarrhythmic drug candidates.

“The new drug candidates may lead to treatment applications in a whole host of cardiovascular conditions that may prove efficacious in clinical trials”... explains senior author Dr. John Cashman. “As antiarrhythmic drug candidate drug development progresses, we expect the new analogs to be less toxic than current therapeutics for arrhythmia in congenital heart disease, and patients will benefit from improved safety, less side effects and possibly with significant cost-savings.”

Summary

Chemists and biologists at HBRI and Stanford University are among the first group to do dynamic medicinal chemistry of deuterated small molecules and a high throughput assay using disease in a dish technology to obtain pharmacologically active compounds of use in cardiovascular disease. New deuterated mexiletine analog compounds selectively blocked sodium channels. To our knowledge, this is one of the first reports to use human iPSC-derived cardiomyocytes from normal and diseased individuals to re-engineer a drug with deficiencies to an entirely new chemotype. Revealing links between drug development and selective human cardiomyocyte sodium channel inhibition might be fundamentally important.

Publication

“Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Cardiovascular Properties and Metabolism and Pharmacokinetics of Deuterated Mexiletine Analogs.” Jorge Gomez-Galeno, Karl Okolotowicz, Mark Johnson, Wesley L. McKeithan, Mark Mercola and John R. Cashman. *Pharmacology Research & Perspectives*.

Media contacts: To arrange on-site, phone, or Skype interviews with the researchers involved in this study, please contact John Cashman at HBRI (858) 458-9305 or JCashman@hbri.org

This research was funded by the California Institute of Regenerative Medicine (CIRM) and the National Institutes of Health.

About Human BioMolecular Research Institute

The Human BioMolecular Research Institute is a non-profit research institute conducting basic research focused on unlocking biological and chemical principles related to diseases of the human brain, cardiovascular disease and cancer. The Institute conducts fundamental studies of central nervous system disorders, heart disease and cancer including stem cell approaches and translates findings into new drug development to

address human illness. In addition, the institute promotes scientific learning through community service and public access by disseminating information and sharing research with collaborators, colleagues and the public. For more information, visit www.HBRI.org.

About Stanford University, Stanford, CA

Stanford University is a leading teaching and research institution. The University is organized around traditional schools consisting of academic departments at the undergraduate and graduate level and professional schools that focus on graduate programs in Law, Medicine, Engineering, and Business. It is recognized for exceptionally high achievement in research, clinical care, education and community outreach and partnerships. For more information, visit www.Stanford.edu.